US Bancorp
SYRS

US Bancorp’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

US Bancorp’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40
Closed -$144 – 4215
2022
Q4 		$144 Hold
40
– – ﹤0.01% 4084
2022
Q3 		$0 Hold
40
– – ﹤0.01% 4249
2022
Q2 		$0 Hold
40
– – ﹤0.01% 4271
2022
Q1 		$0 Hold
40
– – ﹤0.01% 4235
2021
Q4 		$1K Sell
40
-25
-38% -$1.01K ﹤0.01% 4053
2021
Q3 		$3K Sell
65
-56
-46% -$2.73K ﹤0.01% 3829
2021
Q2 		$7K Buy
121
+48
+66% +$2.84K ﹤0.01% 3538
2021
Q1 		$5K Hold
73
– – ﹤0.01% 3516
2020
Q4 		$8K Buy
73
+33
+83% +$3.01K ﹤0.01% 3279
2020
Q3 		$4K Buy
+40
New +$4.54K ﹤0.01% 3374
2018
Q4 		– Sell
-100
Closed -$12K – 3715
2018
Q3 		$12K Hold
100
– – ﹤0.01% 3071
2018
Q2 		$10K Hold
100
– – ﹤0.01% 3146
2018
Q1 		$13K Hold
100
– – ﹤0.01% 3085
2017
Q4 		$10K Buy
+100
New +$13.4K ﹤0.01% 3149

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

US Bancorp's SYRS Position: Q1 2023 in Review

US Bancorp sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2023, closing a stake of 40 shares — an estimated $144 sold.

US Bancorp first reported a position in SYRS in Q4 2017 and held it in 14 quarters. The position peaked at $13K in Q1 2018. 59 funds tracked by Wall St. Rank hold SYRS as of Q1 2023.

  • US Bancorp reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • US Bancorp sold 40 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $144.
  • US Bancorp first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 14 quarters.
  • US Bancorp's Syros Pharmaceuticals, Inc. Common Stock position peaked at $13K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.